Ho, Mei-ShangMei-ShangHoChen, Wei-JuWei-JuChenChen, Hour-YoungHour-YoungChenLin, Szu-FongSzu-FongLinWang, Min-ChinMin-ChinWangDi, JialiJialiDiLu, Yen-TaYen-TaLuLiu, Ching-LungChing-LungLiuSHAN-CHWEN CHANGChao, Chung-LiangChung-LiangChaoKing, Chwan-ChuenChwan-ChuenKingJENG-MIN CHIOUSu, Ih-JenIh-JenSuYang, Jyh-YuanJyh-YuanYang2018-09-102018-09-102005-11http://europepmc.org/abstract/med/16318725http://scholars.lib.ntu.edu.tw/handle/123456789/313461Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of <2 weeks (Fisher exact test, p = 0.013), and were more likely to be > 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development.application/pdf359265 bytesapplication/pdf[SDGs]SDG3neutralizing antibody; severe acute respiratory syndrome vaccine; unclassified drug; virus vaccine; adult; antibody response; antibody titer; article; data analysis; disease severity; female; half life time; high risk patient; human; major clinical study; male; reverse transcription polymerase chain reaction; SARS coronavirus; seroconversion; severe acute respiratory syndrome; survival time; Taiwan; vaccine production; virus detectionjournal article10.3201/eid1111.040659